Biomarkers for Diagnosis and Treatment of Gynecologic Neoplasms
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: closed (20 April 2023) | Viewed by 3522
Special Issue Editor
Special Issue Information
Dear Colleagues,
Ovarian, endometrial, and cervical cancers are the three most common malignancies of the female reproductive organs, and pose a serious threat to women’s health with poor prognosis in advanced stages. Ovarian cancer is the fifth-highest cause of cancer death in women, with more than 200,000 recorded global deaths in 2020. Despite radical cytoreductive surgery combined with chemotherapy and targeted therapies, advanced-stage ovarian cancer patients have a 5-year OS rate of less than 30%. Endometrial carcinoma is the most common malignancy of the female genital tract in developed countries, accounting for nearly 50% of all new gynecologic cancers diagnosed in the Western world. Patients with high-risk factors represent significant therapeutic challenges. Finally, cervical cancer ranks as the fourth most common cancer among women globally, and is one of the most common causes of cancer-related deaths among women worldwide. Patients with advanced or recurrent disease present poor outcomes due to a low response rate to current therapies. Therefore, finding new molecular markers with high sensitivity and specificity for early detection, as well as the discovery of new biomarker-driven targeted therapies, are critical components of reducing morbidity and mortality from gynecologic cancers. Recent technological advances have enabled a remarkably detailed understanding of the distinctive molecular and genomic profiles within gynecologic malignancies. Several studies have provided important insights and molecular tumor characterizations and suggested innovative potential biomarkers for early diagnosis, as well as predictive and prognostic biomarkers. The discovery of these molecular and genomic profiles may provide new targeted therapies, as has already been described with poly-ADP ribose polymerase inhibitors in ovarian cancer. In addition, non-invasive biomarkers (imaging, blood tests, breath tests, etc.) may improve the early diagnosis and prediction of the clinical response.
This Special Issue of Cells is aimed at providing a collection of articles dealing with putative biomarkers for the diagnosis and treatment of gynecologic malignancies. In recent years, there has been an enormous effort to develop specific and sensitive biomarkers for the precise screening, diagnosis, prognosis, and monitoring of high-risk cancer. The identification of new biomarkers is a critical step in the improvement of the diagnosis and treatment of gynecologic malignant tumors.
Dr. Ilan Bruchim
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gynecologic oncology
- uterine cancer
- gynecologic malignant diseases
- ovarian cancer
